Avalo Therapeutics, Inc. (AVTX) has announced the immediate appointment of Mittie Doyle as its new Chief Medical Officer, effective Tuesday.
Bringing over two decades of experience in the pharmaceutical and biotech sectors, Doyle is a seasoned research physician who has held multiple leadership roles in clinical development.
Mittie Doyle joins Avalo from Aro Biotherapeutics, where she has been serving as Chief Medical Officer since 2021.
In conjunction with Doyle's appointment, Avalo's Board has approved the issuance of a non-qualified stock option as part of her employment agreement. This option grants her the ability to purchase 234,000 shares of Avalo's common stock.
